Moreover, cross-trial comparisons suggested that survival outcomes were better with first-line immune checkpoint inhibitors compared to first-line therapy with BRAF/MEKi.12,13 The latter observations were confirmed by the DREAMseq trial, which randomized 265 patients with newly diagnosed metastatic melanoma to the sequence of ipi/nivo followed upon disease progression by dabrafenib plus trametinib versus the inverse sequence, and showed that the 2-year overall survival (OS) rate was superior for those starting with ipi/nivo (71.8% vs. 51.5%; log-rank P = .010).12,14. Here, BRAF is linked to metastatic melanoma.